Clinical trialNCT00831597CompletedPhase 2Interventional

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

SponsorPharmatechEnrollment61Diffuse Large B-Cell Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jeffrey L Vacirca, MD, FACP
University Hospital, Stony Brook North Shore Hematology/Oncology Associates
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Pharmatech Oncology Study Site
Beverly Hills, California, United States
Pharmatech Oncology Study Site
Fountain Valley, California, United States
Pharmatech Oncology Study Site
Oxnard, California, United States
Pharmatech Oncology Study Site
Washington D.C., District of Columbia, United States
Pharmatech Oncology Study Site
Washington D.C., District of Columbia, United States
Pharmatech Oncology Study Site
Boynton Beach, Florida, United States
Pharmatech Oncology Study Site
Brooksville, Florida, United States
Pharmatech Oncology Study Site
Gainesville, Florida, United States
Pharmatech Oncology Study Site
Titusville, Florida, United States
Pharmatech Oncology Study Site
Joliet, Illinois, United States
Pharmatech Oncology Study Site
Lafayette, Indiana, United States
Pharmatech Oncology Study Site
Muncie, Indiana, United States
Pharmatech Oncology Study Site
Dubuque, Iowa, United States
Pharmatech Oncology Study Site
Paducah, Kentucky, United States
Pharmatech Oncology Study Site
York Village, Maine, United States
Pharmatech Oncology Study Site
Jackson, Mississippi, United States
Pharmatech Oncology Study Site
Chesterfield, Missouri, United States
Pharmatech Oncology Study Site
Cherry Hill, New Jersey, United States
Pharmatech Oncology Study Site
Phillipsburg, New Jersey, United States
Pharmatech Oncology Study Site
Bay Shore, New York, United States
Pharmatech Oncology Study Site
East Setauket, New York, United States
Pharmatech Oncology Study Site
The Bronx, New York, United States
Pharmatech Oncology Study Site
Akron, Ohio, United States
Pharmatech Oncology Study Site
Columbus, Ohio, United States
Pharmatech Oncology Study Site
Bethlehem, Pennsylvania, United States
Pharmatech Oncology Study Site
Gettysburg, Pennsylvania, United States
Pharmatech Oncology Study Site
Hilton Head, South Carolina, United States
Pharmatech Oncology Study Site
Germantown, Tennessee, United States
Pharmatech Oncology Study Site
Austin, Texas, United States
Pharmatech Oncology Study Site
Corpus Christi, Texas, United States
Pharmatech Oncology Study Site
Fort Worth, Texas, United States
Pharmatech Oncology Study Site
Lubbock, Texas, United States
Pharmatech Oncology Study Site
Richardson, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2008
Primary completion: 31 Aug 2013
Completion: 30 Sept 2013
Last update posted: 19 Apr 2016
Registered enrollment: 61
Registry id: NCT00831597

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.